Announcement • Aug 04
HealthEquity, Inc. to Report Q2, 2027 Results on Aug 27, 2026 HealthEquity, Inc. announced that they will report Q2, 2027 results Pre-Market on Aug 27, 2026 Announcement • Jun 29
HealthEquity, Inc.(NasdaqGS:HQY) dropped from Russell 2000 Dynamic Index HealthEquity, Inc.(NasdaqGS:HQY) dropped from Russell 2000 Dynamic Index Live News • Jun 13
HealthEquity Lifts Guidance and Expands US$1b Buyback on Strong Q1 and AI Gains HealthEquity reported fiscal Q1 2027 net income up 29% and Adjusted EBITDA up 17%, with Adjusted EBITDA at a 46% margin, on quarterly earnings of $1.24 per share and revenue of $354.64m, above consensus estimates.
Management raised full-year fiscal 2027 guidance and expanded the stock repurchase authorization by US$1b, following completion of a prior buyback program.
The company pointed to growth in Health Savings Account (HSA) enrollment and assets under management, along with AI-driven efficiencies and Marketplace expansion, while continuing to address data security issues tied to a past cybersecurity incident and related litigation and regulatory scrutiny.
The combination of higher guidance, margin expansion and a larger buyback plan indicates management’s confidence in the HSA-focused business model and in the company’s ability to scale operations with technology and AI.
Investors may want to weigh that confidence against ongoing data security, legal and regulatory risks, which could carry financial and reputational implications if outcomes are unfavorable. Live News • Jun 05
HealthEquity Beats Q1 Estimates and Increases Guidance With US$1 Billion Buyback Expansion HealthEquity reported Q1 fiscal 2027 earnings per share of $1.24, ahead of the $1.11 consensus estimate, on revenue of $354.64 million, slightly above expectations.
Net income grew 29% and Adjusted EBITDA rose 17%, with the Adjusted EBITDA margin reaching 46%.
The company raised its fiscal 2027 guidance and expanded its share repurchase authorization by $1 billion, citing disciplined execution, health savings account growth, and AI-supported efficiency gains.
The combination of an earnings beat, higher guidance, and a larger buyback program reflects management’s view of HealthEquity’s cash generation and business momentum.
Investors may want to monitor how AI-enabled cost efficiencies and HSA growth trends evolve alongside increased capital returns through share repurchases. Announcement • May 29
HealthEquity, Inc. Raises Earnings Guidance for the Fiscal Year Ending January 31, 2027 HealthEquity, Inc. raised earnings guidance for the fiscal year ending January 31, 2027. For the fiscal year ending January 31, 2027, management expects revenues of $1.410 billion to $1.420 billion. Its outlook for net income is between $242 million and $248 million, resulting in net income of $2.88 to $2.95 per diluted share. Reported Earnings • May 29
First quarter 2027 earnings: EPS exceeds analyst expectations First quarter 2027 results: EPS: US$0.82 (up from US$0.62 in 1Q 2026). Revenue: US$354.6m (up 7.2% from 1Q 2026). Net income: US$69.4m (up 29% from 1Q 2026). Profit margin: 20% (up from 16% in 1Q 2026). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 22%. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • May 14
HealthEquity, Inc., Annual General Meeting, Jun 25, 2026 HealthEquity, Inc., Annual General Meeting, Jun 25, 2026. Announcement • May 06
HealthEquity, Inc. to Report Q1, 2027 Results on May 28, 2026 HealthEquity, Inc. announced that they will report Q1, 2027 results After-Market on May 28, 2026 Recent Insider Transactions Derivative • Apr 07
Executive VP & CTO notifies of intention to sell stock Elimelech Rosner intends to sell 18k shares in the next 90 days after lodging an Intent To Sell Form on the 31st of March. If the sale is conducted around the recent share price of US$82.53, it would amount to US$1.5m. Since June 2025, Elimelech's direct individual holding has increased from 3.94k shares to 86.27k. Company insiders have collectively sold US$26m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Apr 07
HealthEquity, Inc. Announces Executive Changes, Effective April 17, 2026 On April 6, 2026, HealthEquity, Inc. announced that the employment of Eli Rosner, the Company’s Chief Technology Officer, will be terminated by the Company without cause, effective April 17, 2026. Sunil Rajasekar, the Company’s Executive Vice President, Chief Product and Strategy Officer, will be responsible for overseeing the Company’s technology organization as of that date. Sunil Rajasekar has served as the Company’s Executive Vice President, Chief Product and Strategy Officer since January 2026. Prior to joining HealthEquity, Mr. Rajasekar was the Chief Executive Officer and a director at BTRS Holdings, Inc., d/b/a Billtrust, from November 2022 through August 2025. Prior to serving as Billtrust’s Chief Executive Officer, Mr. Rajasekar served as the President of MINDBODY, Inc. from September 2018 through August 2022. He was a General Manager at eBay Inc. from May 2016 through July 2018, the Chief Technology and Product Officer at Lithium Technologies, Inc. (currently d/b/a Khoros, LLC) and a Vice President at Intuit Inc. from February 2004 to May 2012. Prior to joining Intuit, Mr. Rajasekar held various senior roles at Cisco Corporation and Oracle Corporation. Mr. Rajasekar holds a Bachelor of Commerce from Loyola University and an M.B.A. from the University of Toledo. Announcement • Mar 30
HealthEquity, Inc Appoints William ‘Bill’ Gassen to Its Board of Directors and Audit and Risk Committee and Talent, Compensation and Culture Committee HealthEquity, Inc. announced that William ‘Bill’ Gassen, president and chief executive officer of Sanford Health, has been elected to its board of directors effective March 26, 2026. He will also serve on the Audit and Risk Committee and Talent, Compensation and Culture Committee of the Board. Gassen has served as president and chief executive officer of Sanford Health since November 2020 and is an ex officio member of its board of trustees. Before becoming CEO, Gassen held several senior leadership roles at Sanford Health, including chief administrative officer from January to November 2020, chief human resources officer from July 2016 to January 2020, vice president of human resources integration and corporate services from October 2014 to June 2016, and corporate counsel from February 2012 to September 2014. Before joining Sanford Health, Gassen practiced law in private practice from May 2008 to February 2012. He also serves on the board of directors of Oscar Health, Inc. Gassen holds a bachelor’s degree in criminal justice from the University of South Dakota and a J.D. from the University of South Dakota Knudson School of Law. Reported Earnings • Mar 18
Full year 2026 earnings: EPS exceeds analyst expectations Full year 2026 results: EPS: US$2.50 (up from US$1.11 in FY 2025). Revenue: US$1.31b (up 9.5% from FY 2025). Net income: US$215.2m (up 123% from FY 2025). Profit margin: 16% (up from 8.1% in FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.9%. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Announcement • Mar 18
HealthEquity, Inc. Raises Earnings Guidance for the Fiscal Year Ending January 31, 2027 HealthEquity, Inc. raised earnings guidance for the fiscal year ending January 31, 2027. For the period, the company expects revenues of $1.405 billion to $1.415 billion. Its outlook for net income is between $239 million and $246 million, resulting in net income of $2.78 to $2.85 per diluted share. Announcement • Feb 18
HealthEquity, Inc. to Report Q4, 2026 Results on Mar 17, 2026 HealthEquity, Inc. announced that they will report Q4, 2026 results on Mar 17, 2026 Recent Insider Transactions Derivative • Jan 15
CEO, President & Director notifies of intention to sell stock Scott Cutler intends to sell 12k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of January. If the sale is conducted around the recent share price of US$89.83, it would amount to US$1.1m. Almost all of their compensation in the past year has been non-cash. These sales could comprise a meaningful part of their income for the year. As of today, Scott currently holds no shares directly (This sale likely refers to shares that have not yet been received). Company insiders have collectively sold US$27m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Jan 13
HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2027 HealthEquity, Inc. provided earnings guidance for the fiscal year ending January 31, 2027. For the year, the company expects revenues to be in the range of $1.38 billion to $1.41 billion. Recent Insider Transactions Derivative • Dec 28
Executive VP notifies of intention to sell stock Delano Ladd intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of December. If the sale is conducted around the recent share price of US$95.50, it would amount to US$430k. Since March 2025, Delano's direct individual holding has increased from 39.57k shares to 46.11k. Company insiders have collectively sold US$27m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Dec 21
Executive VP & CTO recently sold US$1.0m worth of stock On the 18th of December, Elimelech Rosner sold around 11k shares on-market at roughly US$95.45 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$18m more than they bought in the last 12 months. Recent Insider Transactions Derivative • Dec 19
Executive VP & CTO notifies of intention to sell stock Elimelech Rosner intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 18th of December. If the sale is conducted around the recent share price of US$95.45, it would amount to US$1.0m. Since March 2025, Elimelech's direct individual holding has increased from 3.61k shares to 10.96k. Company insiders have collectively sold US$26m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Dec 04
Third quarter 2026 earnings: EPS exceeds analyst expectations Third quarter 2026 results: EPS: US$0.60 (up from US$0.065 in 3Q 2025). Revenue: US$322.2m (up 7.2% from 3Q 2025). Net income: US$51.7m (up US$46.0m from 3Q 2025). Profit margin: 16% (up from 1.9% in 3Q 2025). The increase in margin was primarily driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 22%. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • Dec 04
HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2026 HealthEquity, Inc. provided earnings guidance for the fiscal year ending January 31, 2026. For the fiscal year ending January 31, 2026, management expects revenues of $1.302 billion to $1.312 billion. Its outlook for net income is between $197 million and $205 million, resulting in net income of $2.24 to $2.33 per diluted share. Announcement • Nov 06
HealthEquity, Inc. to Report Q3, 2026 Results on Dec 03, 2025 HealthEquity, Inc. announced that they will report Q3, 2026 results After-Market on Dec 03, 2025 Announcement • Oct 14
HealthEquity, Inc. Introduces GLP-1 Telehealth and Direct HSA Enrollment Platforms HealthEquity, Inc. announced two consumer-focused initiatives designed to expand access to affordable healthcare solutions for millions of American families: a curated platform connecting HealthEquity HSA members with affordable healthcare solutions beginning with GLP-1 weight management medications, and a direct HSA enrollment platform. The new offerings coincide with National HSA Awareness Day and the start of open enrollment season. HSAs are experiencing unprecedented growth as Americans seek solutions to rising healthcare costs that leave 44% of adults struggling to afford care. By year-end 2024, HSA assets reached nearly $147 billion across over 39 million accounts, with HSA members spending $42 billion in 2024 alone (up 10% from 2023). These tax-advantaged accounts have become a primary mechanism for healthcare purchasing, signaling a need for increased access to affordable solutions. Introducing HealthEquity GLP-1 Telehealth Offering: HealthEquity's newest offering is a curated platform connecting HSA members with affordable healthcare solution, beginning with GLP-1weight management medications, which goes live today. The offering addresses one of healthcare's fastest-growing cost categories while providing members seamless, tax-advantaged payment options through their HSAs. GLP-1 medications for weight management now represent 6.7% of total drug costs, with some pharmacy coalitions reporting that five GLP-1 drugs account for 21% of overall prescription costs. The new offering, provided in partnership with licensed telehealth provider Agile Telehealth, gives individuals and families access to weight management solutions that are payable using HSA funds for potential tax advantages. The integrated experience enables members to access GLP-1 physician consultations, prescription management, and ongoing care coordination through the HealthEquity app and web portal, with seamless HSA payment processing. HealthEquity also unveiled a direct HSA enrollment platform, a streamlined digital experience enabling individuals to open and fund HSAs directly through HealthEquity's mobile and web platforms. The platform supports a new opportunity created by recent ACA regulatory changes that make Bronze plans HSA-qualified beginning in 2026. This regulatory shift makes over 7 million Americans newly eligible for HSAs, based on 2025 open enrollment data, representing the largest expansion of HSA eligibility since the program's inception. This population--households earning $75,000-$120,000 annually--faces financial pressure as many approach or exceed premium subsidy thresholds while still struggling with healthcare costs. It also features advanced security through Passkey technology and integrates with HealthEquity's partner network of leading health plans to offer seamless enrollment options during open enrollment. Both initiatives support HealthEquity's broader focus to help people better save, spend, and invest for health and are available through the HealthEquity mobile app and HealthEquity.com. Announcement • Sep 26
HealthEquity, Inc. Announces Executive Appointments, Effective September 29, 2025 HealthEquity, Inc. announced the appointment of new senior executives to accelerate the company's strategic vision and capitalize on expanding market opportunities. Mukund Ramachandran joins as Chief Marketing Officer and Garett Kitch as Senior Vice President of Client Sales & Relationship Management, effective September 29, 2025. Ramachandran brings more than 25 years of B2B marketing and communications leadership across fintech, adtech, and martech. Most recently, he served as SVP, Head of B2B Marketing for Commercial & New Payment Flows at Mastercard, where he shaped global messaging, advanced sales enablement, and executed integrated marketing programs that fueled significant growth. Prior to Mastercard, he was a senior marketing leader at Dynamic Yield (later acquired by Mastercard), where he helped transform the company from a startup into a recognized category leader. Earlier in his career, he held marketing and strategy positions across the media and technology sectors, further broadening his expertise in scaling brands and driving market adoption.in his new role, Ramachandran will be responsible for developing and executing HealthEquity’s enterprise-wide marketing strategy. He will lead product marketing and go-to-market execution, while overseeing execution and strategies to strengthen brand reputation and engagement across both B2B and B2C audiences. Kitch joins HealthEquity with two decades of experience building and leading high-performing sales teams in tech-enabled businesses. As Chief Sales Officer at EverQuote, he led revenue-generating functions for the publicly traded insurtech company. Previously, Kitch served in progressive leadership roles at eHealth, Inc., where he led Medicare sales operations with P&L responsibility for $420 million in revenue and managed teams of over 2,200 members. He also held senior positions at Vivint, where he established the Channel Partner division from startup to major acquisition channel.Kitch will define and implement HealthEquity's multi-year sales strategy focused on organic growth, new logo acquisition, and expansion across direct and partner-assisted channels. He will lead efforts to build executive-level relationships with key clients, brokers, and strategic partners while developing differentiated engagement strategies by client segment. The new leadership appointments support HealthEquity's strategic focus on leveraging technology innovation to enhance member and client experiences. The company continues to advance its AI-powered solutions, including expedited claims processing that has automated million of dollars in reimbursements while improving member satisfaction and reducing costs. HealthEquity's Assist portfolio and Member First Secure Mobile Experience, which now boasts 1.7M downloads, demonstrate the company's commitment to technological excellence. Both Ramachandran and Kitch will report to Fiore, strengthening HealthEquity's go-to-market capabilities as the company pursues new consumer-driven strategies while maintaining its leadership position with employers and partners. Recent Insider Transactions Derivative • Sep 21
Executive VP notifies of intention to sell stock Delano Ladd intends to sell 9k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of September. If the sale is conducted around the recent share price of US$95.59, it would amount to US$860k. Since December 2024, Delano's direct individual holding has increased from 38.68k shares to 55.45k. Company insiders have collectively sold US$29m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Sep 03
Second quarter 2026 earnings: EPS and revenues exceed analyst expectations Second quarter 2026 results: EPS: US$0.69 (up from US$0.41 in 2Q 2025). Revenue: US$325.8m (up 8.6% from 2Q 2025). Net income: US$59.9m (up 67% from 2Q 2025). Profit margin: 18% (up from 12% in 2Q 2025). Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates by 39%. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • Sep 03
HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2026 HealthEquity, Inc. provided earnings guidance for the fiscal year ending January 31, 2026. For the fiscal year ending January 31, 2026, management expects revenues of $1.290 billion to $1.310 billion. Its outlook for net income is between $185 million and $200 million, resulting in net income of $2.11 to $2.28 per diluted share. Announcement • Aug 06
HealthEquity, Inc. to Report Q2, 2026 Results on Sep 02, 2025 HealthEquity, Inc. announced that they will report Q2, 2026 results After-Market on Sep 02, 2025 Announcement • Jun 28
HealthEquity, Inc. (NasdaqGS:HQY) announces an Equity Buyback for $300 million worth of its shares. HealthEquity, Inc. (NasdaqGS:HQY) announces a share repurchase program. Under the program, the company will repurchase up to $300 million worth of its common stock. Recent Insider Transactions • Jun 11
Executive VP & CTO recently sold US$8.0m worth of stock On the 9th of June, Elimelech Rosner sold around 71k shares on-market at roughly US$112 per share. This transaction amounted to 95% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$12m more than they bought in the last 12 months. Price Target Changed • Jun 06
Price target increased by 7.4% to US$121 Up from US$113, the current price target is an average from 14 analysts. New target price is 8.3% above last closing price of US$112. Stock is up 31% over the past year. The company is forecast to post earnings per share of US$2.06 for next year compared to US$1.11 last year. Reported Earnings • Jun 04
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: EPS: US$0.62 (up from US$0.33 in 1Q 2025). Revenue: US$330.8m (up 15% from 1Q 2025). Net income: US$53.9m (up 87% from 1Q 2025). Profit margin: 16% (up from 10.0% in 1Q 2025). Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) also surpassed analyst estimates by 50%. Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Announcement • Jun 04
HealthEquity, Inc. Increases Earnings Guidance for the Fiscal Year Ending January 31, 2026 HealthEquity, Inc. increased earnings guidance for the fiscal year ending January 31, 2026. For the period, the company expects revenues of $1.285 billion to $1.305 billion. Its outlook for net income is between $173 million and $188 million, resulting in net income of $1.96 to $2.13 per diluted share. Board Change • Jun 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. CEO, President & Director Scott Cutler was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • May 14
HealthEquity, Inc., Annual General Meeting, Jun 26, 2025 HealthEquity, Inc., Annual General Meeting, Jun 26, 2025. Announcement • May 10
HealthEquity, Inc. to Report Q1, 2026 Results on Jun 03, 2025 HealthEquity, Inc. announced that they will report Q1, 2026 results After-Market on Jun 03, 2025 Recent Insider Transactions Derivative • Apr 11
Independent Non-Executive Chairman notifies of intention to sell stock Robert Selander intends to sell 6k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of April. If the sale is conducted around the recent share price of US$77.65, it would amount to US$447k. Since June 2024, Robert's direct individual holding has increased from 42.26k shares to 75.68k. Company insiders have collectively sold US$11m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Mar 27
Consensus EPS estimates fall by 14% The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate fell from US$2.36 to US$2.02 per share. Revenue forecast steady at US$1.30b. Net income forecast to grow 86% next year vs 29% growth forecast for Healthcare industry in the US. Consensus price target down from US$117 to US$112. Share price rose 5.0% to US$88.83 over the past week. Major Estimate Revision • Mar 25
Consensus EPS estimates increase by 10% The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate increased from US$1.80 to US$1.99. Revenue forecast steady at US$1.30b. Net income forecast to grow 86% next year vs 29% growth forecast for Healthcare industry in the US. Consensus price target down from US$117 to US$113. Share price fell 11% to US$90.19 over the past week. Reported Earnings • Mar 19
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: US$1.11 (up from US$0.65 in FY 2024). Revenue: US$1.20b (up 20% from FY 2024). Net income: US$96.7m (up 74% from FY 2024). Profit margin: 8.1% (up from 5.6% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.9%. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Announcement • Mar 19
HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2026 HealthEquity, Inc. provided earnings guidance for the fiscal year ending January 31, 2026. For the fiscal year ending January 31, 2026, management expects revenues of $1.280 billion to $1.305 billion. Its outlook for net income is between $164 million and $179 million, resulting in net income of $1.85 to $2.01 per diluted share. Announcement • Mar 18
HealthEquity, Inc. Announces the Launch of HealthEquity Assist HealthEquity, Inc. announced the launch of HealthEquity Assist, a suite of tools that help members save, spend, and invest for healthcare. By using HealthEquity Assist, employers are enabled with greater visibility into their benefits program performance and can drive positive financial and health actions to support their workforce. The smart technology offering was developed to alleviate common employee pain points with their benefits -- including rising healthcare costs, which are expected to increase by 9% in 20251, a complex and fragmented benefits landscape that is difficult to navigate, and limited resources available to support benefit education and personalized insights. The three initial HealthEquity Assist offerings integrate quickly into existing company platforms, processes, and workflows. The offerings include: HealthEquity Analyzer™? -- as the analytical foundation of HealthEquity Assist, Analyzer helps employers gain near real-time access to data on inefficiencies, trends, and benefit program design insights. Free of charge and immediately available to HealthEquity clients, this on-demand data allows employers to evaluate performance, mark cost trends, and make smarter decisions. HealthEquity Navigator™? -- simplifies healthcare spending decisions for employees. Navigator provides informed and lower-cost healthcare choices by offering guidance on provider selection, care options, and savings opportunities. Through a partnership with TALON, tools like MyMedicalShopper™? and MyMedicalRewards™? offer price transparency and support to employers looking to reward high-quality, affordable care options. HealthEquity Momentum™? -- empowers employees and employers to be proactive in health and healthcare expense planning. Upon launch, the Momentum platform will drive increased employee engagement with existing benefits programs, nudging healthy behaviors and financial decisions with personalized rewards. Announcement • Feb 19
HealthEquity, Inc. to Report Q4, 2025 Results on Mar 18, 2025 HealthEquity, Inc. announced that they will report Q4, 2025 results on Mar 18, 2025 Recent Insider Transactions Derivative • Feb 11
Independent Non-Executive Chairman notifies of intention to sell stock Robert Selander intends to sell 6k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of February. If the sale is conducted around the recent share price of US$111, it would amount to US$640k. Since June 2024, Robert's direct individual holding has increased from 42.26k shares to 68.93k. Company insiders have collectively sold US$14m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Dec 17
Consensus EPS estimates fall by 10% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from US$1.24 to US$1.12 per share. Revenue forecast steady at US$1.19b. Net income forecast to grow 48% next year vs 28% growth forecast for Healthcare industry in the US. Consensus price target broadly unchanged at US$113. Share price fell 4.5% to US$91.09 over the past week. Recent Insider Transactions • Dec 15
Independent Director recently sold US$2.4m worth of stock On the 12th of December, Stuart Parker sold around 25k shares on-market at roughly US$96.72 per share. This transaction amounted to 82% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$4.4m more than they bought in the last 12 months. New Risk • Dec 10
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 26% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Announcement • Dec 10
HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2025 and Fiscal Year Ending January 31, 2026 HealthEquity, Inc. provided earnings guidance for the fiscal year ending January 31, 2025 and fiscal year ending January 31, 2026. For the fiscal year ending January 31, 2025, management expected revenue of $1.185 billion to $1.195 billion. Its outlook for net income is between $88 million and $96 million, resulting in net income of $0.99 to $1.08 per diluted share.
For the fiscal year ending January 31, 2026, management expected revenue of approximately $1.275 billion to $1.295 billion. These amounts assume an average annualized yield on HSA cash of approximately 3.4% to 3.5%. Announcement • Dec 01
HealthEquity, Inc. and WageWorks, Inc. Settle Their Lawsuit with Union Mesa 1, LLC On November 27, 2024, HealthEquity, Inc. and its wholly owned subsidiary WageWorks, Inc. agreed to settle their lawsuit with Union Mesa 1, LLC related to the termination of a lease in April 2021, which lawsuit was previously disclosed in the Company’s periodic reports on Forms 10-K and 10-Q. Under the terms of the settlement, Union Mesa retained $2.8 million from a letter of credit that it previously received, and the Company and WageWorks jointly agreed to pay Union Mesa an additional $30.0 million. In exchange, the Company, WageWorks and Union Mesa each agreed to dismiss the lawsuit with prejudice and to release the other parties from all claims, as well as all past and future liability under the lease. The Company expects to record the settlement as a merger integration expense in the fiscal quarter ended October 31, 2024, with payment expected to be made during the fiscal quarter ending January 31, 2025. Announcement • Oct 31
HealthEquity, Inc. to Report Q3, 2025 Results on Dec 09, 2024 HealthEquity, Inc. announced that they will report Q3, 2025 results After-Market on Dec 09, 2024 Recent Insider Transactions Derivative • Oct 15
Independent Non-Executive Chairman notifies of intention to sell stock Robert Selander intends to sell 8k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of October. If the sale is conducted around the recent share price of US$82.98, it would amount to US$685k. Since June 2024, Robert's direct individual holding has increased from 42.26k shares to 57.18k. Company insiders have collectively sold US$17m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Oct 15
HealthEquity, Inc Launches HSAnswers HealthEquity, Inc. has launched HSAnswers. Powered by a comprehensive and bespoke database of resources, research, and insights, the free-to-use AI chat tool can help individuals obtain clear answers to questions about HSAs and other consumer-directed benefits. In 2024 HealthEquity surveyed over 600 employees who said their top benefits challenge was being overwhelmed by the amount of information available to them. HSAnswers helps provide the extra support employees are asking for by serving up the answer for them without them having to dig through a mountain of information. HSAnswers offers instant, educational information about HSAs and other benefits. The AI-powered tool does not generate responses outside of the data HealthEquity provides. HSAnswers focuses on content that helps visitors learn about a full range of CDB benefit products and resources including HSAs, FSAs, HRAs, and beyond. HSAnswers provides benefits answers people want when they need it. Instant responses: Users can obtain non-personalized answers to HSA-related inquiries in real-time, reducing the need for third-party support, prolonged web research, or waiting for customer service. Curated knowledge base: Fueled by exhaustive data and information related to consumer-directed benefits, HSAnswers delivers helpful information from HealthEquity’s wealth of content and HSA expertise. User-friendly interface: HSAnswers has a simple user-interface designed for ease of use. Individuals simply click on “HSAnswers” from healthequity.com, follow initial prompts, and ask their HSA or other CDB-related questions. The tool is designed to make CDB answers accessible to everyone from tech-savvy individuals to those less familiar with digital tools. Recent Insider Transactions • Sep 11
Executive VP & CTO recently sold US$947k worth of stock On the 6th of September, Elimelech Rosner sold around 12k shares on-market at roughly US$77.02 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$1.4m more than they bought in the last 12 months. Recent Insider Transactions Derivative • Sep 09
Independent Director notifies of intention to sell stock Stuart Parker intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 6th of September. If the sale is conducted around the recent share price of US$79.49, it would amount to US$2.0m. Since March 2024, Stuart's direct individual holding has decreased from 32.27k shares to 30.66k. Company insiders have collectively sold US$16m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Sep 04
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: EPS: US$0.41 (up from US$0.12 in 2Q 2024). Revenue: US$299.9m (up 23% from 2Q 2024). Net income: US$35.8m (up 239% from 2Q 2024). Profit margin: 12% (up from 4.3% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 5.2%. Earnings per share (EPS) also surpassed analyst estimates by 63%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Announcement • Aug 14
HealthEquity, Inc. to Report Q2, 2025 Results on Sep 03, 2024 HealthEquity, Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Sep 03, 2024 Recent Insider Transactions Derivative • Aug 01
Founder & Vice Chairman exercised options and sold US$2.3m worth of stock On the 25th of July, Stephen Neeleman exercised 35k options at a strike price of around US$14.00 and sold these shares for an average price of US$79.86 per share. This trade did not impact their existing holding. Since December 2023, Stephen's direct individual holding has increased from 807.36k shares to 823.97k. Company insiders have collectively sold US$16m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Jun 27
President notifies of intention to sell stock Jon Kessler intends to sell 46k shares in the next 90 days after lodging an Intent To Sell Form on the 24th of June. If the sale is conducted around the recent share price of US$83.64, it would amount to US$3.8m. For the year to January 2018, Jon's total compensation was 5% salary and 95% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2023, Jon's direct individual holding has decreased from 360.81k shares to 264.50k. Company insiders have collectively sold US$13m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Jun 10
Consensus EPS estimates increase by 15% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from US$1.16b to US$1.17b. EPS estimate increased from US$1.04 to US$1.20 per share. Net income forecast to grow 52% next year vs 29% growth forecast for Healthcare industry in the US. Consensus price target up from US$101 to US$104. Share price rose 5.0% to US$85.25 over the past week. Recent Insider Transactions Derivative • Jun 09
Founder & Vice Chairman notifies of intention to sell stock Stephen Neeleman intends to sell 70k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of June. If the sale is conducted around the recent share price of US$81.22, it would amount to US$5.7m. Since September 2023, Stephen's direct individual holding has increased from 816.47k shares to 823.08k. Company insiders have collectively sold US$11m more than they bought, via options and on-market transactions in the last 12 months. 
